Prognosis
AstraZeneca Worries Complicate Bid to Vaccinate the World
- U.K., EU regulators find possible link to blood clots
- Many countries stick with Astra plans despite new warnings
This article is for subscribers only.
Growing worries that AstraZeneca Plc’s Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul.
Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic.